Published in final edited form as:

Semin Radiat Oncol. 2019 January ; 29(1): 55–61. doi:10.1016/j.semradonc.2018.10.008.

Utilization of vitamin E analogs to protect normal tissues while enhancing anti-tumor effects

Nukhet Aykin-Burns, PhD^a, Rupak Pathak, PhD^a, Marjan Boerma, PhD^{a,*}, Thomas Kim, MD^b, and Martin Hauer-Jensen, MD, PhD^a

University of Arkansas for Medical Sciences

^aDivision of Radiation Health

^bDepartment of Radiation Oncology, 4301 West Markham, Little Rock AR 72205

Abstract

Despite advances in radiation delivery techniques, side effects of radiation therapy due to radiation exposure of normal tissues are common and can limit the deliverable dose to tumors. Significant interests lie in pharmacological modifiers that may protect against normal tissue toxicity from cancer treatment while simultaneously enhancing the tumor response to therapy. While no such treatments are available in the clinic, this is an area of active pre-clinical and clinical research. This review summarizes research studies that provide evidence to indicate that tocotrienols, natural forms of vitamin E, are potent radiation protectors and may also have anti-tumor effects. Hence, several current clinical trials test tocotrienols as concomitant treatment in cancer therapies.

Keywords

Radiation therapy; side effects; tumor growth; tocotrienols; vitamin E

I. Introduction

Approximately half of all cancer patients receive radiation therapy as part of their treatment regimen. Technical improvements in radiation therapy and the combination with novel chemotherapeutic therapies have led to an increase in cancer cure rates. Despite advances in radiation delivery techniques, radiation exposure of the surrounding normal tissues still occurs and can limit the deliverable dose to tumors. Acute and long-term side effects associated with exposure of normal tissues to radiation can affect the quality of life of cancer patients and survivors. Significant interests lie in pharmacological modifiers that may protect

*Corresponding author. University of Arkansas for Medical Sciences, Division of Radiation Health, 4301 West Markham, Slot 522-10, Little Rock, AR 72205. Phone: 501-686-6599. Fax: 501-686-6057 mboerma@uams.edu.

Conflicts of Interest

The University of Arkansas has applied for patent protection on the tocotrienols and other tocotrienol containing products. A potential royalty stream to N.A.-B. and M.H.-J. may occur consistent with the University of Arkansas policy.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

against normal tissue toxicity from cancer treatment while simultaneously enhancing the tumor response to therapy. While no such modifiers have been approved for clinical use, pre-clinical and clinical studies have identified potential safe and effective treatments that may be administered during cancer therapy. This review focuses on tocotrienols, natural forms of vitamin E, as one class of molecules that is an active area of research with much potential.

II. Molecular and cellular properties of tocotrienols

Since its discovery in 1922, vitamin E attracted attention in the biomedical community at an increasing pace (1). Vitamin E is not a single compound, but a general term, which includes the family of lipid soluble tocopherols. These molecules possess structural similarities, yet distinct features and biological properties. All members of the vitamin E family have an aromatic chromanol head determining the nomenclature of the isomers (α -, β -, γ -, and δ -) based on the number of methyl groups located on the chromanol head. Saturation of the 16-carbon hydrocarbon tail also defines the analogs' names as tocopherol (saturated) or tocotrienol (unsaturated) (2).

The putative antioxidant activity of the vitamin E family is believed to arise from the chromanol head. By donating its hydrogen atom and scavenging free radicals in the biological membranes, the phenolic hydroxyl group prevents the propagation of lipid peroxidation (3,4). The accessibility and mobility of the vitamin E analogs also significantly contribute to their antioxidant strength (5–8). Compared to tocopherols, tocotrienols have higher protective potential against lipid peroxidation due to their increased mobility and better distribution in the lipid bilayer, enhancing their ability to interact with lipid radicals in the membranes (9–14). Studies in cell culture indicate that γ -tocotrienol is superior to α -tocopherol in protecting against oxidant injury and subsequent mitochondrial dysfunction (15). Moreover, tocotrienols induce the expression of endogenous antioxidant enzymes including superoxide dismutase (SOD), glutathione peroxidase and NADPH quinoneoxidoreductase (16–18).

In addition to anti-oxidant properties, tocotrienols have many “pleiotropic” effects, as described below, which make tocotrienols attractive molecules in the development of radiation countermeasures.

III. Tocotrienols are potent radiation protectors

III.A Tocotrienols improve survival in animal models of the acute radiation syndrome

Tocotrienols were discovered as strong radiation protectors in animal models of the acute radiation syndrome from whole body exposure to γ - or X-rays (19–26). The optimal time of administration appears to be 24 hours before irradiation. Of all natural compounds tested to date, tocotrienols are among the strongest radiation protectors (27,28). As a result, efforts are underway to develop γ -tocotrienol as a countermeasure against the acute radiation syndrome caused by accidental radiation exposure in human subjects (29).

Although the mechanisms by which tocotrienols protect against the acute radiation syndrome are not yet fully known, pre-clinical studies have provided evidence that

tocotrienols may act at least in part via the induction of granulocyte colony-stimulating factor (GCSF) (30,31). On the other hand, induction of GCSF by γ -tocotrienol is not always associated with potent radiation protection (32), indicating that additional mechanisms of action must be involved. For instance, tocotrienols have anti-inflammatory properties, by suppressing expression of tumor necrosis factor α (TNF α), inducible nitric oxide synthase (iNOS) and interleukins 6 and 8, as well as inhibiting NF- κ B signaling (33–36). Other mechanisms may be discerned from studies on spleen microRNA expression in response to γ -tocotrienol in a mouse models of whole body irradiation (37) and studies on the metabolic response to γ -tocotrienol administration in non-human primates (38).

III.B Tocotrienols protect from radiation injury in part by modifying endothelial cell function

Damage to the vascular endothelial cells plays a critical role in radiation toxicity in various tissues. Therefore, modulation of endothelial cell damage is a promising strategy to use to try to interfere with radiation toxicity. Irrespective of cell type, an early adverse event of radiation exposure is the formation of DNA double strand breaks, which are considered some of the most critical cellular lesions in radiation injury. γ - and δ -Tocotrienol are the only natural forms of vitamin E known to inhibit the cholesterol biosynthesis pathway. They induce the intracellular degradation of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase, the rate-limiting enzyme in cholesterol synthesis (39,40). Moreover, γ -tocotrienol accumulates in 30-fold higher levels than α -tocopherol in endothelial cells (41). As demonstrated in cultured human primary endothelial cells, γ -tocotrienol suppression of radiation-induced DNA double strand break formation and cytogenetic alterations may indicate its therapeutic potential in limiting radiation-induced genetic damage (42).

Inhibition of the cholesterol biosynthesis pathway is associated with increased endothelial expression of thrombomodulin (TM), an endothelial cell surface receptor that has intrinsic anti-inflammatory, anti-oxidant, anti-coagulant, and anti-apoptotic properties (43–46). By forming a complex with the coagulation factor thrombin, TM can exert beneficial effects via generation of activated protein C (APC) (47). Ionizing radiation negatively affects TM expression (48,49), while activation of the APC pathway and administration of exogenous recombinant TM protect against radiation toxicity (50,51). γ -Tocotrienol induces the expression of TM in primary and immortalized human endothelial cells (45). Moreover, γ -tocotrienol-mediated protection against radiation lethality is dependent on TM, indicating the importance of TM in γ -tocotrienol's mechanisms of action (52).

In vitro studies revealed that γ - and δ -tocotrienols are potent inducers of endothelial nitric oxide synthase (eNOS) (53), an enzyme involved in prevention of atherosclerosis, inflammation, oxidative stress and platelet aggregation. Ionizing radiation negatively affects eNOS-mediated nitric oxide (NO) generation, in part due to radiation-induced oxidation of tetrahydrobiopterin, an essential co-factor of eNOS (54,55). As a result, production of superoxide is promoted, a phenomenon popularly known as “eNOS uncoupling”. Uncoupled eNOS enhances generation of peroxynitrite and induces vascular nitrosative stress (56). We have previously shown that γ -tocotrienol suppresses radiation-induced vascular nitrosative stress (57). Co-administration of the HMG-CoA reductase product mevalonate reversed the

effects of γ -tocotrienol, indicating that γ -tocotrienol acted through inhibition of the cholesterol biosynthesis pathway.

Both eNOS and TM are under positive transcriptional control by Kruppel-like factor 2 (KLF2). KLF2 has been associated with endothelial anti-inflammatory, anti-coagulant, antioxidant, anti-adhesive, and anti-permeability properties (58). γ -Tocotrienol and statins synergistically enhance endothelial KLF2 expression as well as the expression and functional activity of TM (45). TM's transcription can also be positively regulated by the transcription factor, heat shock factor 1 (HSF1). Statins cause NO-dependent dissociation of HSF1 from heat shock protein 90, nuclear translocation of HSF1, and binding to heat shock elements in the TM promoter to induce TM expression (44).

Endothelial cells activated through ionizing radiation or other insults express an array of adhesion molecules, including but not limited to intercellular adhesion molecule 1 (ICAM1), vascular cell adhesion molecule 1 (VCAM1), and E-selectin, which allow attachment of hematopoietic immune and non-immune cells to the endothelial surface (59), thereby contributing to inflammation and activation of the coagulation cascade. Tocotrienols suppress lipopolysaccharide-mediated upregulation of ICAM1, VCAM1, and E-selectin in endothelial cells, potentially by inhibiting NF- κ B pathway (53). Moreover, δ -tocotrienol reduces monocyteendothelial cell interaction by inhibiting the surface expression of adhesion molecules in oxysterols- or TNF α -activated human endothelial cells (60,61).

III.C Do tocotrienols reduce adverse tissue remodeling after radiation therapy when administered in combination with pentoxifylline?

Pentoxifylline (PTX) is a phosphodiesterase inhibitor that was first developed as a rheological agent and is currently approved for the treatment of certain vascular diseases (62–64). Because it also has anti-oxidant and anti-inflammatory properties, it has received interest as a potential treatment of fibrosis (65). In fibrosis due to radiation, it has been tested mostly in combination with α -tocopherol. Efficacy of PTX and α -tocopherol against radiation fibrosis has been shown in animal models (66,67) and clinical studies (68,69). In many of these studies treatment with PTX and α -tocopherol is started after radiation-induced fibrosis has become clinically manifest. On the other hand, not all studies show a beneficial effect of PTX and α -tocopherol on radiation fibrosis (70).

[ClinicalTrials.gov](https://clinicaltrials.gov) lists three clinical trials that are recruiting patients to test the impact and safety of PTX and vitamin E against treatment-related toxicity in radiation therapy of head and neck cancer (NCT02397486), non-small cell lung cancer (NCT01871454), and metastatic brain cancer (NCT01508221).

Although some studies suggest that PTX enhances the radiation protective properties of γ -tocotrienol (71,72), additional studies are required to determine whether PTX combined with a tocotrienol may be a better radiation protector or mitigator than combined with α -tocopherol.

IV. Tocotrienols have anti-cancer properties

In addition to the protection against normal tissue radiation injury as described above, several studies show that tocotrienols have cancer preventive properties (73–76). Stable and unstable structural changes in chromosomes are considered the “hallmark” features of cancer cells. Administration of γ -tocotrienol 24 hours before total body irradiation in a mouse model suppresses cytogenetic alterations in bone marrow cells (42). Other suggested mechanisms of cancer prevention by γ -tocotrienol include anti-inflammatory activities and direct effects on cancer cell proliferation and death (77,78).

In addition to cancer prevention, researchers are exploring the therapeutic role of tocotrienols in cancers (79–82). Here we present a selection of studies published in this area. Tocotrienols have cytotoxic properties against cancer cells in culture (83–87). Many molecular mechanisms have been proposed, including induction of the mitochondrial apoptosis pathway (88,89), altered sphingolipid metabolism (90), endoplasmic reticulum stress (91), inhibition of telomerase (92), inhibition of signaling pathways involved in cytoskeletal organization (93) induction of cyclin dependent kinase inhibitors p21 and p27 (94), inhibition of canonical Wnt signaling (95), and modification of the Ras-ERK pathway (96).

Tocotrienols have shown efficacy against tumor growth in *in vivo* models. For instance, γ -tocotrienol reduced tumor growth in mouse models of human colorectal cancer (97). Similarly, a tocotrienol-rich fraction inhibited the growth of human colon cancer xenografts in a mouse model (98). δ -Tocotrienol inhibited tumor growth and number of metastases in a mouse model of orthotopic human pancreatic ductal adenocarcinoma (99). Oxazine derivatives of γ - and δ -tocotrienols showed enhanced anti-tumor activities compared to regular γ - and δ -tocotrienol in a syngeneic mouse model of breast cancer (100). While mechanisms by which oxazine derivation enhances anti-tumor activity are not yet exactly known, mechanisms may involve attenuation of mammary tumor cell compensatory response to hypoxia (101).

Angiogenesis is an important pathological process during tumor development. Vascular endothelial growth factor (VEGF) is one of the critical pro-angiogenic factors, which is upregulated by hypoxia-inducible factor-1, a transcription factor induced under hypoxic conditions but also by ionizing radiation (102,103). Tocotrienols have anti-angiogenic effects via down-regulating VEGF expression, indicating that tocotrienols have the potential to restrict tumor growth by exerting anti-angiogenic effects (104–107). For instance, γ -tocotrienol reduced tumor growth in a mouse model of human hepatocellular carcinoma, together with indications of anti-angiogenesis effects (108).

V. *In vivo* bioavailability of tocotrienols

Despite the advantages in the cellular effects of tocotrienols over tocopherols, lower *in vivo* bioavailability of tocotrienols as compared to that of tocopherols may decrease its effectiveness (109,110). Both tocopherols and tocotrienols are cleaved by esterases and absorbed in the small intestine. Following absorption, both tocopherols and tocotrienols

undergo a similar pattern for transportation to the lymphatic system via chylomicrons (111). The major obstacle for tocotrienols' bioavailability following oral administration arises from their initial tissue distribution via α -tocopherol transfer protein (α TTP). While this hepatic protein has an excellent affinity for α -tocopherol, its affinity for tocotrienols is less because the unsaturated isoprenoid chain of tocotrienols obstruct the α TTP binding pocket (112–114).

Concerns related to bioavailability of tocotrienols after oral administration have led to the development of self-emulsifying formulations for enhanced intestinal absorption (115,116). In addition, tocotrienol absorption is enhanced when taken together with food (110,117). Other recent developments in the advancement of novel anti-cancer approaches with tocotrienols include the PEGylating γ - and δ -tocotrienol for enhanced bioavailability (118), or synthesis of nano-emulsions or new tumor-targeted nano-capsules loaded with anti-cancer medications and tocotrienols (119–124).

VI. Clinical development of tocotrienols

Tocotrienols are safe, non-toxic and well tolerated dietary supplements that exhibit no known interactions with other medications (125,126). Based on the broad evidence of antiradiation toxicity and anti-cancer properties of tocotrienols in pre-clinical and clinical studies, current clinical trials test tocotrienols as concomitant treatment in cancer therapies. Several clinical trials currently listed in [ClinicalTrials.gov](https://clinicaltrials.gov) are recruiting patients to test tocotrienols in the treatment of cancer. δ -Tocotrienol is tested in combination with standard chemotherapy in nonsmall cell lung cancer (NCT02644252). Also, efficacy and safety of tocotrienol (isomer not specified) is tested in patients who have developed chemo-resistant ovarian cancer (NCT02560337), and tocotrienol (isomer not specified) is tested in combination with bevacizumab in advanced ovarian cancer (NCT02399592). Tocotrienol (isomer not specified) is used to improve efficacy of neoadjuvant chemotherapy in breast cancer (NCT02909751). Lastly, a trial is testing whether tocotrienol (isomer not specified) can reduce side effects of 5fluorouracil, oxaliplatin, irinotecan (FOLFOXIRI) in metastatic colorectal cancer (NCT02705300).

VII. Conclusions

In conclusion, tocotrienols have a high safety profile and do not interfere with other medications. Pre-clinical and clinical evidence support the use of tocotrienols to reduce tumor growth and protect normal tissues from radiation injury, making tocotrienols attractive compounds that may increase both efficacy and safety of cancer treatment.

Acknowledgments

Grant support

National Institute of General Medical Sciences (P20 GM109005), College of Pharmacy seed funding

References

1. Evans HM, Bishop KS. On the existence of a hitherto unrecognized dietary factor essential for reproduction. *Science* 1922;56(1458):650–1. [PubMed: 17838496]
2. Machlin LJ. *Handbook of Vitamins*. New York: Marcel Dekker, Inc., 1991.
3. McCay PB. Vitamin E: interactions with free radicals and ascorbate. *Annu Rev Nutr* 1985;5:323–40. [PubMed: 2992548]
4. Emanuel NM, Liaskovskaia IN. *The inhibition of fat oxidation processes*. Oxford: Pergamon Press, 1967.
5. Barclay LR. The cooperative antioxidant role of glutathione with a lipid-soluble and a watersoluble antioxidant during peroxidation of liposomes initiated in the aqueous phase and in the lipid phase. *J Biol Chem* 1988;263(31):16138–42. [PubMed: 3182788]
6. Niki E, Kawakami A, Saito M, Yamamoto Y, Tsuchiya J, Kamiya Y. Effect of phytol side chain of vitamin E on its antioxidant activity. *J Biol Chem* 1985;260(4):2191–6. [PubMed: 3972787]
7. Niki E. Antioxidants in relation to lipid peroxidation. *Chem Phys Lipids* 1987;44(2–4):227–53. [PubMed: 3311418]
8. Niki E, Komuro E. Inhibition of peroxidation of membranes. *Basic Life Sci* 1988;49:561–6. [PubMed: 3250511]
9. Hayes KC, Pronczuk A, Liang JS. Differences in the plasma transport and tissue concentrations of tocopherols and tocotrienols: observations in humans and hamsters. *Proc Soc Exp Biol Med* 1993;202(3):353–9. [PubMed: 8437992]
10. Suzuki YJ, Tsuchiya M, Wassall SR, Choo YM, Govil G, Kagan VE, Packer L. Structural and dynamic membrane properties of alpha-tocopherol and alpha-tocotrienol: implication to the molecular mechanism of their antioxidant potency. *Biochemistry* 1993;32(40):106929.
11. Komiya K, Iizuka K, Yamaoka M, Watanabe H, Tsuchiya N, Umezawa I. Studies on the biological activity of tocotrienols. *Chem Pharm Bull (Tokyo)* 1989;37(5):1369–71. [PubMed: 2630104]
12. Kamat JP, Sarma HD, Devasagayam TP, Nesaretnam K, Basiron Y. Tocotrienols from palm oil as effective inhibitors of protein oxidation and lipid peroxidation in rat liver microsomes. *Mol Cell Biochem* 1997;170(1–2):131–7. [PubMed: 9144327]
13. Kamat JP, Devasagayam TP. Tocotrienols from palm oil as potent inhibitors of lipid peroxidation and protein oxidation in rat brain mitochondria. *Neurosci Lett* 1995;195(3):179–82. [PubMed: 8584204]
14. Nakano M, Sugioka K, Nakamura T, Oki T. Interaction between an organic hydroperoxide and an unsaturated phospholipid and alpha-tocopherol in model membranes. *Biochim Biophys Acta* 1980;619(2):274–86. [PubMed: 7407212]
15. Nowak G, Bakajsova D, Hayes C, Hauer-Jensen M, Compadre CM. gamma-Tocotrienol protects against mitochondrial dysfunction and renal cell death. *J Pharmacol Exp Ther* 2012;340(2):330–8. [PubMed: 22040679]
16. Adam A, Marzuki A, Ngah WZ, Top GM. Nitrofurantoin-induced hepatic and pulmonary biochemical changes in mice fed different vitamin E doses. *Pharmacol Toxicol* 1996;79(6):334–9. [PubMed: 9000262]
17. Lee SP, Mar GY, Ng LT. Effects of tocotrienol-rich fraction on exercise endurance capacity and oxidative stress in forced swimming rats. *Eur J Appl Physiol* 2009;107(5):587–95. [PubMed: 19705143]
18. Newaz MA, Nawal NN. Effect of gamma-tocotrienol on blood pressure, lipid peroxidation and total antioxidant status in spontaneously hypertensive rats (SHR). *Clin Exp Hypertens* 1999;21(8):1297–313. [PubMed: 10574414]
19. Li XH, Ghosh SP, Ha CT, Fu D, Elliott TB, Bolduc DL, Villa V, Whitnall MH, Landauer MR, Xiao M. Delta-tocotrienol protects mice from radiation-induced gastrointestinal injury. *Radiat Res* 2013;180(6):649–57. [PubMed: 24294967]
20. Suman S, Datta K, Chakraborty K, Kulkarni SS, Doiron K, Fornace AJ, Jr., Sree KK, Hauer-Jensen M, Ghosh SP. Gamma tocotrienol, a potent radioprotector, preferentially upregulates

- expression of anti-apoptotic genes to promote intestinal cell survival. *Food Chem Toxicol* 2013;60:488–96. [PubMed: 23941772]
21. Satyamitra MM, Kulkarni S, Ghosh SP, Mullaney CP, Condliffe D, Srinivasan V. Hematopoietic recovery and amelioration of radiation-induced lethality by the vitamin E isoform delta-tocotrienol. *Radiat Res* 2011;175(6):736–45. [PubMed: 21434782]
 22. Li XH, Fu D, Latif NH, Mullaney CP, Ney PH, Mog SR, Whitnall MH, Srinivasan V, Xiao M. Delta-tocotrienol protects mouse and human hematopoietic progenitors from gamma irradiation through extracellular signal-regulated kinase/mammalian target of rapamycin signaling. *Haematologica* 2010;95(12):1996–2004. [PubMed: 20823133]
 23. Kulkarni S, Ghosh SP, Satyamitra M, Mog S, Hieber K, Romanyukha L, Gambles K, Toles R, Kao TC, Hauer-Jensen M, Kumar KS. Gamma-tocotrienol protects hematopoietic stem and progenitor cells in mice after total-body irradiation. *Radiat Res* 2010;173(6):738–47. [PubMed: 20518653]
 24. Ledet GA, Biswas S, Kumar VP, Graves RA, Mitchner DM, Parker TM, Bostanian LA, Ghosh SP, Mandal TK. Development of Orally Administered gamma-Tocotrienol (GT3) Nanoemulsion for Radioprotection. *Int J Mol Sci* 2016;18(1).
 25. Singh VK, Kulkarni S, Fatanmi OO, Wise SY, Newman VL, Romaine PL, Hendrickson H, Gulani J, Ghosh SP, Kumar KS, Hauer-Jensen M. Radioprotective Efficacy of GammaTocotrienol in Nonhuman Primates. *Radiat Res* 2016;185(3):285–98. [PubMed: 26930378]
 26. Li XH, Ha CT, Fu D, Landauer MR, Ghosh SP, Xiao M. Delta-tocotrienol suppresses radiation-induced microRNA-30 and protects mice and human CD34+ cells from radiation injury. *PLoS One* 2015;10(3):e0122258. [PubMed: 25815474]
 27. Ghosh SP, Kulkarni S, Hieber K, Toles R, Romanyukha L, Kao TC, Hauer-Jensen M, Kumar KS. Gamma-tocotrienol, a tocol antioxidant as a potent radioprotector. *Int J Radiat Biol* 2009;85(7):598–606. [PubMed: 19557601]
 28. Singh VK, Kulkarni S, Fatanmi OO, Wise SY, Newman VL, Romaine PL, Hendrickson H, Gulani J, Ghosh SP, Kumar KS, Hauer-Jensen M. Radioprotective Efficacy of GammaTocotrienol in Nonhuman Primates. *Radiat Res* 2016;185(3):285–98. [PubMed: 26930378]
 29. Singh VK, Beattie LA, Seed TM. Vitamin E: tocopherols and tocotrienols as potential radiation countermeasures. *J Radiat Res* 2013;54(6):973–88. [PubMed: 23658414]
 30. Singh VK, Wise SY, Scott JR, Romaine PL, Newman VL, Fatanmi OO. Radioprotective efficacy of delta-tocotrienol, a vitamin E isoform, is mediated through granulocyte colony-stimulating factor. *Life Sci* 2014;98(2):113–22. [PubMed: 24486300]
 31. Kulkarni S, Singh PK, Ghosh SP, Posarac A, Singh VK. Granulocyte colony-stimulating factor antibody abrogates radioprotective efficacy of gamma-tocotrienol, a promising radiation countermeasure. *Cytokine* 2013;62(2):278–85. [PubMed: 23561424]
 32. Banerjee S, Shah SK, Melnyk SB, Pathak R, Hauer-Jensen M, Pawar SA. Cebpd Is Essential for Gamma-Tocotrienol Mediated Protection against Radiation-Induced Hematopoietic and Intestinal Injury. *Antioxidants (Basel)* 2018;7(4).
 33. Kuhad A, Bishnoi M, Tiwari V, Chopra K. Suppression of NF-kappabeta signaling pathway by tocotrienol can prevent diabetes associated cognitive deficits. *Pharmacol Biochem Behav* 2009;92(2):251–9. [PubMed: 19138703]
 34. Norazlina M, Maizatul-Neza J, Azarina A, Nazrun AS, Norliza M, Ima-Nirwana S. Effects of vitamin E on receptor activator of nuclear factor kappa B ligand (RANKL) and osteoprotegerin (OPG) in rats treated with nicotine. *Med J Malaysia* 2010;65(1):14–7. [PubMed: 21265240]
 35. Ahmad NS, Khalid BA, Luke DA, Ima NS. Tocotrienol offers better protection than tocopherol from free radical-induced damage of rat bone. *Clin Exp Pharmacol Physiol* 2005;32(9):761–70. [PubMed: 16173934]
 36. Wu SJ, Liu PL, Ng LT. Tocotrienol-rich fraction of palm oil exhibits anti-inflammatory property by suppressing the expression of inflammatory mediators in human monocytic cells. *Mol Nutr Food Res* 2008;52(8):921–9. [PubMed: 18481320]
 37. Ghosh SP, Pathak R, Kumar P, Biswas S, Bhattacharyya S, Kumar VP, Hauer-Jensen M, Biswas R. Gamma-Tocotrienol Modulates Radiation-Induced MicroRNA Expression in Mouse Spleen. *Radiat Res* 2016;185(5):485–95. [PubMed: 27128741]

38. Cheema AK, Mehta KY, Fatanmi OO, Wise SY, Hinzman CP, Wolff J, Singh VK. A Metabolomic and Lipidomic Serum Signature from Nonhuman Primates Administered with a Promising Radiation Countermeasure, Gamma-Tocotrienol. *Int J Mol Sci* 2017;19(1).
39. Parker RA, Pearce BC, Clark RW, Gordon DA, Wright JJ. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. *J Biol Chem* 1993;268(15):11230–8. [PubMed: 8388388]
40. Song BL, Bose-Boyd RA. Insig-dependent ubiquitination and degradation of 3-hydroxy-3-methylglutaryl coenzyme A reductase stimulated by delta- and gamma-tocotrienols. *J Biol Chem* 2006;281(35):25054–61. [PubMed: 16831864]
41. Berbee M, Fu Q, Boerma M, Sree KK, Loose DS, Hauer-Jensen M. Mechanisms underlying the radioprotective properties of gamma-tocotrienol: comparative gene expression profiling in tocotrienol-treated endothelial cells. *Genes Nutr* 2012;7:75–81. PMID: PMC3250525. [PubMed: 21516479]
42. Pathak R, Bachri A, Ghosh SP, Koturbash I, Boerma M, Binz RK, Sawyer JR, Hauer-Jensen M. The Vitamin E Analog Gamma-Tocotrienol (GT3) Suppresses Radiation-Induced Cytogenetic Damage. *Pharm Res* 2016;33(9):2117–25. [PubMed: 27216753]
43. Abeyama K, Stern DM, Ito Y, Kawahara K, Yoshimoto Y, Tanaka M, Uchimura T, Ida N, Yamazaki Y, Yamada S, Yamamoto Y, Yamamoto H, Iino S, Taniguchi N, Maruyama I. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. *J Clin Invest* 2005;115(5):1267–74. [PubMed: 15841214]
44. Fu Q, Wang J, Boerma M, Berbee M, Qiu X, Fink LM, Hauer-Jensen M. Involvement of Heat Shock Factor 1 in Statin-Induced Transcriptional Upregulation of Endothelial Thrombomodulin. *Circ Res* 2008;103(4):369–77. [PubMed: 18599869]
45. Pathak R, Ghosh SP, Zhou D, Hauer-Jensen M. The Vitamin E Analog Gamma-Tocotrienol (GT3) and Statins Synergistically Up-Regulate Endothelial Thrombomodulin (TM). *Int J Mol Sci* 2016;17(11).
46. Masamura K, Oida K, Kanehara H, Suzuki J, Horie S, Ishii H, Miyamori I. Pitavastatin-induced thrombomodulin expression by endothelial cells acts via inhibition of small G proteins of the Rho family. *Arterioscler Thromb Vasc Biol* 2003;23(3):512–7. [PubMed: 12615662]
47. Van de Wouwer M, Collen D, Conway EM. Thrombomodulin-protein C-EPCR system: 2004;24(8):1374–83.
48. Richter KK, Fink LM, Hughes BM, Sung CC, Hauer-Jensen M. Is the loss of endothelial thrombomodulin involved in the mechanism of chronicity in late radiation enteropathy? *Radiotherapy & Oncology* 1997;44(1):65–71. [PubMed: 9288860]
49. Wang J, Zheng H, Ou X, Fink LM, Hauer-Jensen M. Deficiency of microvascular thrombomodulin and up-regulation of protease-activated receptor-1 in irradiated rat intestine: possible link between endothelial dysfunction and chronic radiation fibrosis. *Am J Pathol* 2002;160(6):2063–72. [PubMed: 12057911]
50. Pathak R, Wang J, Garg S, Aykin-Burns N, Petersen KU, Hauer-Jensen M. Recombinant Thrombomodulin (Solulin) Ameliorates Early Intestinal Radiation Toxicity in a Preclinical Rat Model. *Radiat Res* 2016;186(2):112–20. [PubMed: 27459702]
51. Geiger H, Pawar SA, Kerschen EJ, Nattamai KJ, Hernandez I, Liang HP, Fernandez JA, Cancelas JA, Ryan MA, Kustikova O, Schambach A, Fu Q, Wang J, Fink LM, Petersen KU, Zhou D, Griffin JH, Baum C, Weiler H, Hauer-Jensen M. Pharmacological targeting of the thrombomodulin-activated protein C pathway mitigates radiation toxicity. *Nat Med* 2012;18(7):1123–9. [PubMed: 22729286]
52. Pathak R, Shao L, Ghosh SP, Zhou D, Boerma M, Weiler H, Hauer-Jensen M. Thrombomodulin contributes to gamma tocotrienol-mediated lethality protection and hematopoietic cell recovery in irradiated mice. *PLoS One* 2015;10(4):e0122511. [PubMed: 25860286]
53. Muid S, Froemming GR, Rahman T, Ali AM, Nawawi HM. Delta- and gamma-tocotrienol isomers are potent in inhibiting inflammation and endothelial activation in stimulated human endothelial cells. *Food Nutr Res* 2016;60:31526. [PubMed: 27396399]
54. Pathak R, Cheema AK, Boca SM, Krager KJ, Hauer-Jensen M, Aykin-Burns N. Modulation of Radiation Response by the Tetrahydrobiopterin Pathway. *Antioxidants (Basel)* 2015;4(1):68–81. [PubMed: 26785338]

55. Vasquez-Vivar J, Kalyanaraman B, Martasek P. The role of tetrahydrobiopterin in superoxide generation from eNOS: enzymology and physiological implications. *Free Radic Res* 2003;37(2): 121–7. [PubMed: 12653200]
56. Rafikov R, Fonseca FV, Kumar S, Pardo D, Darragh C, Elms S, Fulton D, Black SM. eNOS activation and NO function: structural motifs responsible for the posttranslational control of endothelial nitric oxide synthase activity. *J Endocrinol* 2011;210(3):271–84. [PubMed: 21642378]
57. Berbee M, Fu Q, Boerma M, Wang J, Kumar KS, Hauer-Jensen M. gamma-Tocotrienol ameliorates intestinal radiation injury and reduces vascular oxidative stress after totalbody irradiation by an HMG-CoA reductase-dependent mechanism. *Radiat Res* 2009;171(5):596–605. [PubMed: 19580495]
58. Atkins GB, Jain MK. Role of Kruppel-like transcription factors in endothelial biology. *Circ Res* 2007;100(12):1686–95. [PubMed: 17585076]
59. Quarmby S, Kumar P, Kumar S. Radiation-induced normal tissue injury: role of adhesion molecules in leukocyte-endothelial cell interactions. *Int J Cancer* 1999;82(3):385–95. [PubMed: 10399956]
60. Naito Y, Shimozawa M, Kuroda M, Nakabe N, Manabe H, Katada K, Kokura S, Ichikawa H, Yoshida N, Noguchi N, Yoshikawa T. Tocotrienols reduce 25-hydroxycholesterol-induced monocyte-endothelial cell interaction by inhibiting the surface expression of adhesion molecules. *Atherosclerosis* 2005;180(1):19–25. [PubMed: 15823271]
61. Chao JT, Gapor A, Theriault A. Inhibitory effect of delta-tocotrienol, a HMG CoA reductase inhibitor, on monocyte-endothelial cell adhesion. *J Nutr Sci Vitaminol (Tokyo)* 2002;48(5):332–7. [PubMed: 12656204]
62. Stefanovich V. Effect of pentoxifylline on energy rich phosphates in rat's erythrocytes. *Res Commun Chem Pathol Pharmacol* 1975;10(4):747–50. [PubMed: 1153851]
63. Ganser V, Boksay I. Effect of pentoxifylline on cerebral edema in cats. *Neurology* 1974;24(5):487–93. [PubMed: 4363819]
64. Lossnitzer K, Raptis S, Grebe B, Muller R. The influence of 3,7-dimethyl-1-(5-oxo-hexyl)xanthine (pentoxifylline, BL 191) on serum calcium and magnesium levels. *Arzneimittelforschung* 1973;23(7):938–40. [PubMed: 4800449]
65. Wen WX, Lee SY, Siang R, Koh RY. Repurposing Pentoxifylline for the Treatment of Fibrosis: An Overview. *Adv Ther* 2017;34(6):1245–69. [PubMed: 28484954]
66. Boerma M, Roberto KA, Hauer-Jensen M. Prevention and treatment of functional and structural radiation injury in the rat heart by pentoxifylline and alpha-tocopherol. *Int J Radiat Oncol Biol Phys* 2008;72(1):170–7. PMID: PMC2574608. [PubMed: 18632215]
67. Liu H, Xiong M, Xia YF, Cui NJ, Lu RB, Deng L, Lin YH, Rong TH. Studies on pentoxifylline and tocopherol combination for radiation-induced heart disease in rats. *Int J Radiat Oncol Biol Phys* 2009;73(5):1552–9. [PubMed: 19306752]
68. Hille A, Christiansen H, Pradier O, Hermann RM, Siekmeyer B, Weiss E, Hilgers R, Hess CF, Schmidberger H. Effect of pentoxifylline and tocopherol on radiation proctitis/enteritis. *Strahlenther Onkol* 2005;181(9):606–14. [PubMed: 16170489]
69. Delanian S, Porcher R, Rudant J, Lefaix JL. Kinetics of response to long-term treatment combining pentoxifylline and tocopherol in patients with superficial radiation-induced fibrosis. *J Clin Oncol* 2005;23(34):8570–9. [PubMed: 16260695]
70. Gothard L, Cornes P, Earl J, Hall E, MacLaren J, Mortimer P, Peacock J, Peckitt C, Woods M, Yarnold J. Double-blind placebo-controlled randomised trial of vitamin E and pentoxifylline in patients with chronic arm lymphoedema and fibrosis after surgery and radiotherapy for breast cancer. *Radiother Oncol* 2004;73(2):133–9. [PubMed: 15542159]
71. Berbee M, Fu Q, Garg S, Kulkarni S, Kumar KS, Hauer-Jensen M. Pentoxifylline enhances the radioprotective properties of gamma-tocotrienol: differential effects on the hematopoietic, gastrointestinal and vascular systems. *Radiat Res* 2011;175(3):297–306. [PubMed: 21388273]
72. Kulkarni S, Chakraborty K, Kumar KS, Kao TC, Hauer-Jensen M, Ghosh SP. Synergistic radioprotection by gamma-tocotrienol and pentoxifylline: role of cAMP signaling. *ISRN Radiol* 2013;2013:390379. [PubMed: 24959559]

73. Wilankar C, Khan NM, Checker R, Sharma D, Patwardhan R, Gota V, Sandur SK, Devasagayam TP. gamma-Tocotrienol induces apoptosis in human T cell lymphoma through activation of both intrinsic and extrinsic pathways. *Curr Pharm Des* 2011;17(21):2176–89. [PubMed: 21774779]
74. Jiang Q Natural Forms of Vitamin E as Effective Agents for Cancer Prevention and Therapy. *Adv Nutr* 2017;8(6):850–67. [PubMed: 29141970]
75. Sylvester PW, Akl MR, Malaviya A, Parajuli P, Ananthula S, Tiwari RV, Ayoub NM. Potential role of tocotrienols in the treatment and prevention of breast cancer. *Biofactors* 2014;40(1):49–58. [PubMed: 23804535]
76. Campbell S, Stone W, Whaley S, Krishnan K. Development of gamma (gamma)-tocopherol as a colorectal cancer chemopreventive agent. *Crit Rev Oncol Hematol* 2003;47(3):24959.
77. Abubakar IB, Lim KH, Kam TS, Loh HS. Enhancement of apoptotic activities on brain cancer cells via the combination of gamma-tocotrienol and jerantinine A. *Phytomedicine* 2017;30:74–84. [PubMed: 28545672]
78. Alawin OA, Ahmed RA, Ibrahim BA, Briski KP, Sylvester PW. Antiproliferative effects of gamma-tocotrienol are associated with lipid raft disruption in HER2-positive human breast cancer cells. *J Nutr Biochem* 2016;27:266–77. [PubMed: 26507543]
79. Ling MT, Luk SU, Al-Ejeh F, Khanna KK. Tocotrienol as a potential anticancer agent. *Carcinogenesis* 2012;33(2):233–9. [PubMed: 22095072]
80. Sailo BL, Banik K, Padmavathi G, Javadi M, Bordoloi D, Kunnumakkara AB. Tocotrienols: The promising analogues of vitamin E for cancer therapeutics. *Pharmacol Res* 2018.
81. Shanmugam MK, Warriar S, Kumar AP, Sethi G, Arfuso F. Potential Role of Natural Compounds as Anti-Angiogenic Agents in Cancer. *Curr Vasc Pharmacol* 2017;15(6):503–19. [PubMed: 28707601]
82. De SL, Chuah LH, Meganathan P, Fu JY. Tocotrienol and cancer metastasis. *Biofactors* 2016;42(2):149–62. [PubMed: 26948691]
83. Kaneko S, Sato C, Shiozawa N, Sato A, Sato H, Virgona N, Yano T. Suppressive Effect of Delta-Tocotrienol on Hypoxia Adaptation of Prostate Cancer Stem-like Cells. *Anticancer Res* 2018;38(3):1391–9. [PubMed: 29491063]
84. Marzagalli M, Moretti RM, Messi E, Marelli MM, Fontana F, Anastasia A, Bani MR, Beretta G, Limonta P. Targeting melanoma stem cells with the Vitamin E derivative deltatocotrienol. *Sci Rep* 2018;8(1):587. [PubMed: 29330434]
85. Sato C, Kaneko S, Sato A, Virgona N, Namiki K, Yano T. Combination Effect of deltaTocotrienol and gamma-Tocopherol on Prostate Cancer Cell Growth. *J Nutr Sci Vitaminol (Tokyo)* 2017;63(5):349–54. [PubMed: 29225320]
86. Yeganehjoo H, DeBose-Boyd R, McFarlin BK, Mo H. Synergistic Impact of d-deltaTocotrienol and Geranylgeraniol on the Growth and HMG CoA Reductase of Human DU145 Prostate Carcinoma Cells. *Nutr Cancer* 2017;69(4):682–91. [PubMed: 28362175]
87. Ding Y, Peng Y, Deng L, Fan J, Huang B. Gamma-tocotrienol reverses multidrug resistance of breast cancer cells with a mechanism distinct from that of atorvastatin. *J Steroid Biochem Mol Biol* 2017;167:67–77. [PubMed: 27864002]
88. Xu W, Mi Y, He P, He S, Niu L. gamma-Tocotrienol Inhibits Proliferation and Induces Apoptosis Via the Mitochondrial Pathway in Human Cervical Cancer HeLa Cells. *Molecules* 2017;22(8).
89. Tan JK, Then SM, Mazlan M, Raja Abdul Rahman RN, Jamal R, Wan Ngah WZ. Gammatocotrienol acts as a BH3 mimetic to induce apoptosis in neuroblastoma SH-SY5Y cells. *J Nutr Biochem* 2016;31:28–37. [PubMed: 27133421]
90. Jang Y, Rao X, Jiang Q. Gamma-tocotrienol profoundly alters sphingolipids in cancer cells by inhibition of dihydroceramide desaturase and possibly activation of sphingolipid hydrolysis during prolonged treatment. *J Nutr Biochem* 2017;46:49–56. [PubMed: 28456081]
91. Comitato R, Guantario B, Leoni G, Nesaretnam K, Ronci MB, Canali R, Virgili F. Tocotrienols induce endoplasmic reticulum stress and apoptosis in cervical cancer cells. *Genes Nutr* 2016;11:32. [PubMed: 28031751]
92. Eitsuka T, Tatewaki N, Nishida H, Nakagawa K, Miyazawa T. A Combination of deltaTocotrienol and Ferulic Acid Synergistically Inhibits Telomerase Activity in DLD-1 Human Colorectal Adenocarcinoma Cells. *J Nutr Sci Vitaminol (Tokyo)* 2016;62(5):281–7. [PubMed: 27928113]

93. Algayadh IG, Dronamraju V, Sylvester PW. Role of Rac1/WAVE2 Signaling in Mediating the Inhibitory Effects of gamma-Tocotrienol on Mammary Cancer Cell Migration and Invasion. *Biol Pharm Bull* 2016;39(12):1974–82. [PubMed: 27904039]
94. Huang Y, Wu R, Su ZY, Guo Y, Zheng X, Yang CS, Kong AN. A naturally occurring mixture of tocotrienols inhibits the growth of human prostate tumor, associated with epigenetic modifications of cyclin-dependent kinase inhibitors p21 and p27. *J Nutr Biochem* 2017;40:155–63. [PubMed: 27889685]
95. Ahmed RA, Alawin OA, Sylvester PW. gamma-Tocotrienol reversal of epithelial-to-mesenchymal transition in human breast cancer cells is associated with inhibition of canonical Wnt signalling. *Cell Prolif* 2016;49(4):460–70. [PubMed: 27323693]
96. Burdeos GC, Ito J, Eitsuka T, Nakagawa K, Kimura F, Miyazawa T. delta and gamma tocotrienols suppress human hepatocellular carcinoma cell proliferation via regulation of Ras-Raf-MEK-ERK pathway-associated upstream signaling. *Food Funct* 2016;7(10):4170–4. [PubMed: 27713963]
97. Prasad S, Gupta SC, Tyagi AK, Aggarwal BB. gamma-Tocotrienol suppresses growth and sensitises human colorectal tumours to capecitabine in a nude mouse xenograft model by down-regulating multiple molecules. *Br J Cancer* 2016;115(7):814–24. [PubMed: 27575851]
98. Zhang JS, Zhang SJ, Li Q, Liu YH, He N, Zhang J, Zhou PH, Li M, Guan T, Liu JR. Tocotrienol-rich fraction (TRF) suppresses the growth of human colon cancer xenografts in Balb/C nude mice by the Wnt pathway. *PLoS One* 2015;10(3):e0122175. [PubMed: 25807493]
99. Husain K, Centeno BA, Coppola D, Trevino J, Sebti SM, Malafa MP. delta-Tocotrienol, a natural form of vitamin E, inhibits pancreatic cancer stem-like cells and prevents pancreatic cancer metastasis. *Oncotarget* 2017;8(19):31554–67. [PubMed: 28404939]
100. Ananthula S, Parajuli P, Behery FA, Alayoubi AY, El Sayed KA, Nazzal S, Sylvester PW. Oxazine derivatives of gamma- and delta-tocotrienol display enhanced anticancer activity in vivo. *Anticancer Res* 2014;34(6):2715–26. [PubMed: 24922632]
101. Ananthula S, Parajuli P, Behery FA, Alayoubi AY, Nazzal S, El SK, Sylvester PW. deltaTocotrienol oxazine derivative antagonizes mammary tumor cell compensatory response to CoCl2-induced hypoxia. *Biomed Res Int* 2014;2014:285752. [PubMed: 25140303]
102. Fu Z, Chen D, Cheng H, Wang F. Hypoxia-inducible factor-1alpha protects cervical carcinoma cells from apoptosis induced by radiation via modulation of vascular endothelial growth factor and p53 under hypoxia. *Med Sci Monit* 2015;21:318–25. [PubMed: 25623525]
103. Gu Q, He Y, Ji J, Yao Y, Shen W, Luo J, Zhu W, Cao H, Geng Y, Xu J, Zhang S, Cao J, Ding WQ. Hypoxia-inducible factor 1alpha (HIF-1alpha) and reactive oxygen species (ROS) mediates radiation-induced invasiveness through the SDF-1alpha/CXCR4 pathway in non-small cell lung carcinoma cells. *Oncotarget* 2015;6(13):10893–907. [PubMed: 25843954]
104. Weng-Yew W, Selvaduray KR, Ming CH, Nesaretnam K. Suppression of tumor growth by palm tocotrienols via the attenuation of angiogenesis. *Nutr Cancer* 2009;61(3):367–73. [PubMed: 19373610]
105. Shibata A, Nakagawa K, Sookwong P, Tsuduki T, Oikawa S, Miyazawa T. deltaTocotrienol suppresses VEGF induced angiogenesis whereas alpha-tocopherol does not. *J Agric Food Chem* 2009;57(18):8696–704. [PubMed: 19702331]
106. Selvaduray KR, Radhakrishnan AK, Kutty MK, Nesaretnam K. Palm tocotrienols decrease levels of pro-angiogenic markers in human umbilical vein endothelial cells (HUVEC) and murine mammary cancer cells. *Genes Nutr* 2012;7(1):53–61. [PubMed: 21526401]
107. Miyazawa T, Shibata A, Sookwong P, Kawakami Y, Eitsuka T, Asai A, Oikawa S, Nakagawa K. Antiangiogenic and anticancer potential of unsaturated vitamin E (tocotrienol). *J Nutr Biochem* 2009;20(2):79–86. [PubMed: 19071006]
108. Siveen KS, Ahn KS, Ong TH, Shanmugam MK, Li F, Yap WN, Kumar AP, Fong CW, Tergaonkar V, Hui KM, Sethi G. Y-tocotrienol inhibits angiogenesis-dependent growth of human hepatocellular carcinoma through abrogation of AKT/mTOR pathway in an orthotopic mouse model. *Oncotarget* 2014;5(7):1897–911. [PubMed: 24722367]
109. Patel V, Khanna S, Roy S, Ezziddin O, Sen CK. Natural vitamin E alpha-tocotrienol: retention in vital organs in response to long-term oral supplementation and withdrawal. *Free Radic Res* 2006;40(7):763–71. [PubMed: 16984003]

110. Fairus S, Nor RM, Cheng HM, Sundram K. Postprandial metabolic fate of tocotrienol-rich vitamin E differs significantly from that of alpha-tocopherol. *Am J Clin Nutr* 2006;84(4):835–42. [PubMed: 17023711]
111. Hensley K, Benaksas EJ, Bolli R, Comp P, Grammas P, Hamdheydari L, Mou S, Pye QN, Stoddard MF, Wallis G, Williamson KS, West M, Wechter WJ, Floyd RA. New perspectives on vitamin E: gamma-tocopherol and carboxyethylhydroxychroman metabolites in biology and medicine. *Free Radic Biol Med* 2004;36(1):1–15. [PubMed: 14732286]
112. Compadre CM, Singh A, Thakkar S, Zheng G, Breen PJ, Ghosh S, Kiaei M, Boerma M, Varughese KI, Hauer-Jensen M. Molecular dynamics guided design of tocoflexol: a new radioprotectant tocotrienol with enhanced bioavailability. *Drug Dev Res* 2014;75(1):1022.
113. Min KC, Kovall RA, Hendrickson WA. Crystal structure of human alpha-tocopherol transfer protein bound to its ligand: implications for ataxia with vitamin E deficiency. *Proc Natl Acad Sci U S A* 2003;100(25):14713–8. [PubMed: 14657365]
114. Meier R, Tomizaki T, Schulze-Briesche C, Baumann U, Stocker A. The molecular basis of vitamin E retention: structure of human alpha-tocopherol transfer protein. *J Mol Biol* 2003;331(3):725–34. [PubMed: 12899840]
115. Meganathan P, Fu JY. Biological Properties of Tocotrienols: Evidence in Human Studies. *Int J Mol Sci* 2016;17(11).
116. Yap SP, Yuen KH. Influence of lipolysis and droplet size on tocotrienol absorption from self-emulsifying formulations. *Int J Pharm* 2004;281(1–2):67–78. [PubMed: 15288344]
117. Yap SP, Yuen KH, Wong JW. Pharmacokinetics and bioavailability of alpha-, gamma- and delta-tocotrienols under different food status. *J Pharm Pharmacol* 2001;53(1):67–71. [PubMed: 11206194]
118. Gopalan Y, Shuaib IL, Magosso E, Ansari MA, Abu Bakar MR, Wong JW, Khan NA, Liong WC, Sundram K, Ng BH, Karuthan C, Yuen KH. Clinical investigation of the protective effects of palm vitamin E tocotrienols on brain white matter. *Stroke* 2014;45(5):1422–8. [PubMed: 24699052]
119. Mahalingam D, Radhakrishnan AK, Amom Z, Ibrahim N, Nesaretnam K. Effects of supplementation with tocotrienol-rich fraction on immune response to tetanus toxoid immunization in normal healthy volunteers. *Eur J Clin Nutr* 2011;65(1):63–9. [PubMed: 20859299]
120. Abu-Fayyad A, Nazzal S. Synthesis, characterization, and in-vitro antitumor activity of the polyethylene glycol (350 and 1000) succinate derivatives of the tocopherol and tocotrienol isomers of Vitamin E. *Int J Pharm* 2017;519(1–2):145–56. [PubMed: 28093324]
121. Nasr M, Nafee N, Saad H, Kazem A. Improved antitumor activity and reduced cardiotoxicity of epirubicin using hepatocyte-targeted nanoparticles combined with tocotrienols against hepatocellular carcinoma in mice. *Eur J Pharm Biopharm* 2014;88(1):216–25. [PubMed: 24813390]
122. Daifuku R, Koratich M, Stackhouse M. Vitamin E Phosphate Nucleoside Prodrugs: A Platform for Intracellular Delivery of Monophosphorylated Nucleosides. *Pharmaceuticals (Basel)* 2018;11(1).
123. Abu-Fayyad A, Kamal MM, Carroll JL, Dragoi AM, Cody R, Cardelli J, Nazzal S. Development and in-vitro characterization of nanoemulsions loaded with paclitaxel/gamma-tocotrienol lipid conjugates. *Int J Pharm* 2018;536(1):146–57. [PubMed: 29195915]
124. Tan DM, Fu JY, Wong FS, Er HM, Chen YS, Nesaretnam K. Tumor regression and modulation of gene expression via tumor-targeted tocotrienol niosomes. *Nanomedicine (Lond)* 2017;12(20):2487–502. [PubMed: 28972460]
125. Abu-Fayyad A, Nazzal S. Gemcitabine-vitamin E conjugates: Synthesis, characterization, entrapment into nanoemulsions, and in-vitro deamination and antitumor activity. *Int J Pharm* 2017;528(1–2):463–70. [PubMed: 28627455]
126. Karim R, Somani S, Al RM, Mullin M, Amor R, McConnell G, Dufes C. Tumor regression after intravenous administration of targeted vesicles entrapping the vitamin E alphatocotrienol. *J Control Release* 2017;246:79–87. [PubMed: 27993600]

127. Mahipal A, Klapman J, Vignesh S, Yang CS, Neuger A, Chen DT, Malafa MP. Pharmacokinetics and safety of vitamin E delta-tocotrienol after single and multiple doses in healthy subjects with measurement of vitamin E metabolites. *Cancer Chemother Pharmacol* 2016;78(1):157–65. [PubMed: 27278668]
128. Springett GM, Husain K, Neuger A, Centeno B, Chen DT, Hutchinson TZ, Lush RM, Sebt S, Malafa MP. A Phase I Safety, Pharmacokinetic, and Pharmacodynamic Presurgical Trial of Vitamin E delta-tocotrienol in Patients with Pancreatic Ductal Neoplasia. *EBioMedicine* 2015;2(12):1987–95. [PubMed: 26844278]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript